Funding for this research was provided by:
National Cancer Center Research and Development Fund (29-A-3)
Received: 15 July 2020
Accepted: 25 September 2020
First Online: 1 October 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of National Cancer Center (reference number, 2018–242). Approval for the review of hospital records was obtained from the Institutional Review Board of National Cancer Center and the patients’ informed consent was waived given the retrospective nature of the study.
: Not applicable.
: Yasuyuki Kawamoto has received speaking honoraria from Taiho Pharmaceutical and Lilly. Makoto Ueno has received research funding from Taiho Pharmaceutical and Yakult Honsha, and speaking honoraria from Taiho Pharmaceutical and Yakult Honsha. The other authors have no conflict of interest.